Investor desk
Watch for partnership announcements between health systems and specialty pharma; PBM-adjacent vendors (data, AI, hub services) often preview enterprise deals here.
← Back to Events
Tier 1 Global Networking: High ONCOLOGY CONCLUDED
THMA Oncology Forum — 2026 — Fort Lauderdale, USA
Explore the top pharmacy conferences in 2026. Get executive insights on 340B reform, IRA drug pricing, and AI adoption from Asembia, ASHP, and THMA forums.
500+ Attendees
4 Presentations
1 Companies
Presentation data updated Jun 15, 2026, 9:40 AM UTC
Why This Event Matters
Explore the top pharmacy conferences in 2026.
Industry impact
Explore the top pharmacy conferences in 2026.
Market implications
Expect signals on PBM–provider alignment, biosimilar tendering, and ambulatory margin recovery as systems negotiate manufacturer contracts.
Regulatory implications
FDA real-world evidence pilots and 340B policy uncertainty shape how pharmacy leaders justify evidence-generation and access investments.
Investor implications
Watch for partnership announcements between health systems and specialty pharma; PBM-adjacent vendors (data, AI, hub services) often preview enterprise deals here.
Competitive implications
Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Event Significance
Tier-1 industry catalyst
58 /100 composite
THMA Oncology Forum is a targeted oncology forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: downstream media and analyst follow-through.
- Media coverage 20/20
High follow-on media and sell-side note volume expected within 24–48h of key sessions.
- Speaker quality 15/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Pipeline relevance 1/20
Early science or services-focused — lower near-term PDUFA linkage.
- Historical influence 20/20
Prior editions moved stock prices and label expansions — expect similar volatility windows.
- Company participation 2/20
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
Nova Pharma Intelligence · Analyst desk
Key Takeaways
- Dana-Farber Cancer Institute carries 3 tracked presentations — map against peer readouts at THMA Oncology Forum.
- Watch for partnership announcements between health systems and specialty pharma; PBM-adjacent vendors (data, AI, hub services) often preview enterprise deals here.
- FDA real-world evidence pilots and 340B policy uncertainty shape how pharmacy leaders justify evidence-generation and access investments.
Timeline & Milestones
- Pre-event intelligence Complete
4 presentations tracked — Key Data and Companies hubs live.
- Conference opens May 6, 2026 Complete
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Complete
5 Nova articles linked — see Coverage & Analysis.
- Conference closes May 8, 2026 Complete
Post-event recap, competitive takeaways, and trial updates.
Oncology BD teams Clinical development leaders Investors & analysts
Executive Summary
C-level briefExplore the top pharmacy conferences in 2026.
Primary audience: Oncology BD teams · Clinical development leaders · Investors & analysts
Analyst Watch
Regulatory affairs
FDA real-world evidence pilots and 340B policy uncertainty shape how pharmacy leaders justify evidence-generation and access investments.
Competitive intelligence
Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
vs. Prior Editions
| Edition | Presentations | Companies |
|---|---|---|
| THMA Oncology Forum (current) | 4 | 1 |
| THMA Pharmacy Growth (2026) | 6 | 0 |
| THMA CPE Circle (2026) | 1 | 0 |
Most Anticipated Presentations
Full data hub → LATE-BREAKER
Late-breaking results in breast cancer
LATE-BREAKER
Late-breaking results in [another cancer type]
ORAL
Prognostic and predictive impact of [specific biomarker] in breast cancer
PLENARY
Two plenary studies in pancreatic and prostate cancer
Competitive Landscape
Company map →Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Companies to Watch
All companies →Coverage & Analysis
3 articlesRelated News & Research
Research hub →Event Intelligence Summary
Standalone summaries for THMA Oncology Forum — optimized for research and AI retrieval.
Executive Summary
Explore the top pharmacy conferences in 2026.
Analyst View
Explore the top pharmacy conferences in 2026.
Investor View
Watch for partnership announcements between health systems and specialty pharma; PBM-adjacent vendors (data, AI, hub services) often preview enterprise deals here.
BD View
BD teams should prioritize networking with presenting companies and services vendors at THMA Oncology Forum, focusing on oncology partnership and licensing opportunities.
Key Facts
- Event
- THMA Oncology Forum
- Focus
- oncology
- Region
- US Americas
- Attendance
- 500+
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is THMA Oncology Forum?
THMA Oncology Forum is a oncology industry conference bringing together executives, clinical leaders, and investors to discuss pipeline, regulatory, and commercial strategy.
Who attends THMA Oncology Forum?
Typical attendees include pharma executives, BD teams, investors, regulatory affairs professionals, and clinical operations leaders focused on oncology.
Why is THMA Oncology Forum important?
THMA Oncology Forum influences partnership timing, pipeline prioritization, and policy debates that affect oncology markets for the next 12–18 months.
When is THMA Oncology Forum?
THMA Oncology Forum takes place on the scheduled dates.
Where is THMA Oncology Forum held?
THMA Oncology Forum is held in the listed venue.
How many attendees does THMA Oncology Forum attract?
THMA Oncology Forum typically draws 500+ attendees from across the oncology ecosystem.
What companies participate at THMA Oncology Forum?
1+ companies present data or participate in programming at THMA Oncology Forum, spanning large pharma, biotech, and services vendors.
What should investors watch at THMA Oncology Forum?
Investors should track partnership announcements, pipeline readouts, M&A signals, and management commentary on oncology catalysts during and after THMA Oncology Forum.
What BD opportunities exist at THMA Oncology Forum?
BD teams use THMA Oncology Forum for licensing discussions, co-development talks, and vendor selection across oncology — especially in networking sessions and satellite meetings.
How does THMA Oncology Forum compare with other pharma conferences?
THMA Oncology Forum is a tier-1 global congress for oncology — compare speaker quality, company participation, and historical deal flow with peer events in the same therapeutic or commercial vertical.
How do I get NovaPharmaNews coverage of THMA Oncology Forum?
NovaPharmaNews publishes pre-event briefs, live coverage, and post-event analysis for THMA Oncology Forum. Subscribe to event alerts on this page for breaking updates.